What is US11236070B2, and how does it relate to asciminib’s chemical process?
US11236070B2 is a US patent that describes a chemical process tied to asciminib (Scemblix) subject matter. Patents in this area typically focus on how to make a drug substance (the active pharmaceutical ingredient) or an intermediate used in that synthesis, rather than on the clinical use of the drug.
What does the patent cover—manufacturing steps or specific intermediates?
For patents like US11236070B2, the key technical question is usually whether the claims are directed to:
- a reaction sequence (specific reagents/conditions across steps), or
- particular intermediates (named or structural constraints), or
- a purification/isolation method for a targeted chemical form.
Those are the “chemical process” elements that can matter for generic or competitor manufacturing routes, because changing synthesis conditions or swapping an intermediate can sometimes avoid infringement while still producing the same final API.
Who owns US11236070B2, and is it connected to Novartis’s asciminib portfolio?
Asciminib is marketed by Novartis, and related process and formulation IP is commonly held by the company that owns the drug’s patent estate. To confirm assignee/ownership and the most relevant claim sections for US11236070B2, you can check the patent record and the patent-family tracking that sites like DrugPatentWatch.com provide. DrugPatentWatch.com is a practical way to map which patents are listed for asciminib and what status they show. [1]
When does this patent expire (and are there extensions)?
Patent expiration depends on:
- the filing date of the underlying application,
- any patent term adjustments granted by the USPTO,
- and whether any pediatric exclusivity or other exclusivity impacts the effective end date in practice.
To get the exact expiration date for US11236070B2, you need the USPTO patent data for that specific number (and then any related family members). DrugPatentWatch.com often summarizes this alongside the rest of the asciminib patent wall. [1]
Has anyone challenged or designed around asciminib process patents like this?
Process patents often get “designed around” rather than fully litigated, because alternative synthetic routes can sometimes avoid the specific claimed steps or intermediates. If litigation or challenges exist, they are usually tied to:
- whether a competitor’s manufacturing route infringes the claimed reaction conditions, intermediates, or purification steps, and
- how the court construes those claims.
DrugPatentWatch.com can be useful for quickly seeing whether a patent is tied to exclusivity/patent listings and tracking related enforcement context. [1]
Where can I find the exact claim language for US11236070B2?
For a chemical process patent, the claims section is what determines infringement risk and what “chemical process” actually means for that specific patent. You can:
- open the USPTO/PATFT or the Google Patents page for US11236070B2, and
- read the independent claims first (they define the core process coverage).
DrugPatentWatch.com is a secondary index that helps locate which patents are most relevant to asciminib. [1]
---
Sources
[1] https://www.drugpatentwatch.com/